Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2015
Context: The filing discloses a Japanese report ("Kessan Tanshin") filed with the Tokyo Stock Exchange containing financial results for the quarter ended June 30, 2015, and a full-year forecast for 2015.
Key Financial Metrics
Historical Results (Q2 2015): The filing references the Form 10-Q for the quarter ended June 30, 2015, but does not explicitly state the specific revenue, profit, or cash flow figures for this period within the text provided.
Full Year 2015 Forecast:
- Revenues: $0 (Forecasted as "$ -")
- Operating Loss: $10,943,000
- Net Loss: $10,943,000
- Expected Loss Per Share (Basic & Diluted): $0.39
- Weighted Average Shares: 27,500,000
Currency Translation: Supplementary financial statements in Japanese yen were translated at a rate of 122.45 JPY per USD (as of June 30, 2015).
Material Changes and Comparisons
The filing does not provide specific numerical comparisons to the prior comparable period (Q2 2014 or FY 2014) within the text. It notes that the Tanshin is substantially the same as the Form 10-Q except for the inclusion of the supplemental full-year forecast and yen-denominated statements.
Guidance, Outlook, and Risks
Management Commentary: The forecast is based on management's assumptions regarding current conditions and trends. Management believes these assumptions are reasonable but cannot assure that actual results will align with estimates.
Risks and Uncertainties:
- Actual results may differ materially from estimates due to factors beyond the Company's control.
- Independent auditors have not compiled or reviewed the forecasted results and assume no responsibility for their accuracy.
- Forward-looking statements involve risks regarding regulatory approval, clinical trial progress, product efficacy, patent protection, and capital market conditions.
- The Company undertakes no obligation to update forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the specific Q2 2015 revenue and expense figures in the referenced Form 10-Q, as they are not detailed in this 8-K.
- Confirm the weighted average share count of 27,500,000 used for the EPS calculation.
- Review the Form 10-K for the year ended December 31, 2014, for detailed risk factors referenced in the forecast disclaimer.
- Monitor the Company's ability to raise capital, given the forecasted operating loss of approximately $10.9 million and zero revenue.